CPI-1205
(Synonyms:CPI-1205)
目录号 : KG10425
CAS No. : 1621862-70-1
纯度 : 98%
0.002 μM for biochemical IC50; 0.032 μM for cellular EC50.
CPI-1205 is an EZH2 inhibitor.
Polycomb repressive complex 2 (PRC2) plays a key role in transcriptional silencing partially by installing methylation marks on lysine 27 of histone 3. Dysregulation of PRC2 function relates with certain malignancies and poor prognosis. EZH2 is thus representing a promising candidate oncology target for pharmacological intervention.
In vitro: Previous study reported that the treatment with CPI-1205 caused apoptosis in multiple myeloma and plasmacytoma cell models. CPI-1205 also had a clean selectivity profile when tested against 30 other histone or DNA methyltransferases. In addition, CPI-1205 demonstrated modest selectivity when tested against enhancer of zeste homologue 1 (EZH1) that is a methyltransferase highly related to EZH2 .
In vivo: In animal study, CPI-1205 was dosed at 160 mg/kg orally twice daily for 25 days in tumor bearing female CB-17 SCID mice. By the treatment of tumor-bearing mice with CPI-1205, tumor regression was observed within two weeks. By the end of day 25, significant tumor growth inhibition was recorded. CPI-1205 was found to be well-tolerated for repeat dosing as observed by the absence of significant body weight loss. In addition, analysis of plasma and tumor at 1 h post last dose on day 25 showed sufficient plasma and tumor tissue concentrations .
Clinical trial: A study to evaluate CPI-1205 in patients with B-cell lymphomas is currently recruiting participants .
Other Forms of Rapamycin:
KKL Med 的所有产品和服务仅用于科学研究,不能被用于人体,兽医,我们也不向个人提供产品和服务。
KKL 顾客使用本产品发表的 0 篇科研文献
暂无科研文献
分子式 |
C27H33F3N4O3
|
分子量 |
518.57
|
CAS号 |
1621862-70-1
|
中文名称 |
CPI-1205
|
储存方式 |
Store at -20°C
|